Anti-αGal-dependent complement-mediated cytotoxicity in metastatic melanoma
- 1 April 2006
- journal article
- research article
- Published by Wolters Kluwer Health in Melanoma Research
- Vol. 16 (2) , 157-163
Abstract
Antibodies to the cell surface disaccharide galactose(α1,3)galactose (αGal) are the most prevalent natural antibodies in human serum. The anti-αGal immunoglobulin M-dependent activation of complement causes hyperacute rejection of organ transplants from discordant species by human recipients. It has been shown in vitro that human tumour cells transduced with the gene that synthesizes αGal become sensitive to human serum. A prerequisite for anti-αGal antibody-based therapeutic strategies is that patients with cancer have adequate serum levels of anti-αGal immunoglobulins and complement. The objective of this work was to measure the levels and function of anti-αGal immunoglobulins and complement in the serum of patients with metastatic melanoma and healthy volunteers. Serum complement levels were assayed by radial immunodiffusion. Anti-αGal immunoglobulin G and immunoglobulin M titres were measured by enzyme-linked immunosorbent assay. Disaccharide sugar blocking was used to investigate antibody specificity. The functional integrity of anti-αGal antibodies and complement was investigated in cell lysis assays. It was found that the levels of the complement components C1q, C3 and C4 and the function of the classical complement pathway were normal in metastatic melanoma patients. Anti-αGal antibody titres were as variable in metastatic melanoma patients as in healthy controls, and the lysis of αGal-expressing cells correlated with anti-αGal immunoglobulin M titre (P<0.0001). Anti-αGal antibody titres, complement levels and overall cytolytic function in the serum of patients with metastatic melanoma were indistinguishable from those of healthy controls. There is thus nothing intrinsic to the disease that will limit anti-αGal-based therapeutic strategies for enhanced antigen presentation or induced cell lysis, including the mimicry of hyperacute rejection.Keywords
This publication has 29 references indexed in Scilit:
- Decrease of human pancreatic cancer cell tumorigenicity by ?1,3galactosyltransferase gene transferInternational Journal of Cancer, 2003
- Expression of α-gal epitopes on ovarian carcinoma membranes to be used as a novel autologous tumor vaccineGynecologic Oncology, 2003
- ANTI-GAL??1???3GAL ANTIBODY LEVELS IN ORGAN TRANSPLANT RECIPIENTS RECEIVING IMMUNOSUPPRESSIVE THERAPYTransplantation, 2000
- Induction of complement attack on human cells by Gal(alpha1,3)Gal xenoantigen expression as a gene therapy approach to cancerGene Therapy, 1999
- A MURINE MODEL OF ANTIBODY-MEDIATED HYPERACUTE REJECTION BY GALACTOSE-??(1,3)GALACTOSE ANTIBODIES IN Gal o/o MICE1Transplantation, 1998
- Antibody Levels against α-Galactosyl Epitopes in Sera of Patients with Squamous Intraepithelial Lesions and Early Invasive Cervical CarcinomaGynecologic Oncology, 1997
- Early Events in Cell‐Mediated Recognition of Vascularized Xenografts: Cooperative Interactions between Selected Lymphocyte Subsets and Natural AntibodiesImmunological Reviews, 1994
- Generation of Interleukin-2-Secreting Melanoma Cell Populations from Resected Metastatic TumorsHuman Gene Therapy, 1994
- Identification of α-galactosyl and other carbohydrate epitopes that are bound by human anti-pig antibodies: relevance to discordant xenografting in manTransplant Immunology, 1993
- IMMUNOPATHOLOGY OF HYPERACUTE XENOGRAFT REJECTION IN A SWINE-TO-PRIMATE MODELTransplantation, 1991